HIMS Hims & Hers Health, Inc.
Services-Offices & Clinics of Doctors of Medicine · NYSE · SEC CIK 1773751 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.8%
TTM net income YoY-242.6%
TTM EPS YoY-256.6%
Revenue 3-yr CAGR53.6%
Net income 3-yr CAGR—
Margins
Gross margin63.8%
Operating margin-8.1%
Net margin-6.7%
FCF margin0.3%
EBITDA margin-4.3%
Returns
ROE-40.8%
ROA-6.6%
ROIC (approx.)—
Asset turnover0.99x
Leverage & solvency
Liabilities / assets90.0%
Debt / equity0.00x
Current ratio0.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.94x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue6.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.35B | $1.48B |
| Cost of revenue | $614.26M | $303.38M |
| Gross profit | $1.73B | $1.17B |
| SG&A expense | $272.72M | $167.77M |
| Operating income | $105.61M | $61.90M |
| Pretax income | $123.92M | $71.71M |
| Income tax | -$4.44M | -$54.33M |
| Net income | $128.37M | $126.04M |
| EBITDA | $160.12M | $78.99M |
| EPS (basic) | 0.57 | 0.58 |
| EPS (diluted) | 0.51 | 0.53 |
| Weighted avg. shares (diluted) | 258.23M | 236.81M |
| Balance sheet | ||
| Cash & equivalents | $228.62M | $221.44M |
| Short-term investments | $348.88M | $79.67M |
| Receivables | $32.15M | $6.10M |
| Inventory | $80.13M | $64.43M |
| Current assets | $767.64M | $395.83M |
| Goodwill | $278.32M | $112.73M |
| Intangibles | $196.12M | $43.41M |
| Total assets | $2.15B | $707.54M |
| Current liabilities | $404.43M | $221.37M |
| Total liabilities | $1.61B | $230.82M |
| Shareholders' equity | $540.93M | $476.72M |
| Cash flow statement | ||
| Operating cash flow | $300.01M | $251.08M |
| Capital expenditure | $242.60M | $52.80M |
| Free cash flow | $57.41M | $198.28M |
| Investing cash flow | -$1.02B | -$19.05M |
| Financing cash flow | $729.62M | -$107.84M |
| Depreciation & amortization | $54.50M | $17.09M |
| Stock-based compensation | $135.24M | $92.32M |
| Share buybacks | $89.96M | $83.04M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.